Announcement • May 19
Enlivex Ltd Announces Dosing of First Patient in the United States as Part of Phase 2B Trial of Allocetra in Age-Related Primary Moderate-To-Severe Knee Osteoarthritis Enlivex Ltd. announced the dosing of the first patient at a United States clinical site in the Phase 2b clinical trial of Allocetra™ for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis (OA). The global, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial is designed to evaluate the efficacy and safety of intra-articular injections of Allocetra™ in patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis, which is one of the most prevalent and disabling diseases worldwide, affecting more than 32 million Americans today and projected to impact 78 million Americans by 2040. The trial is enrolling patients from clinical centers in the United States, Denmark and Poland. Key efficacy endpoints include changes from baseline of pain and physical function compared with placebo, measured at three- and six-month periods following treatment. Additional endpoints include changes in quality-of-life measures and functional mobility assessments. Knee osteoarthritis (KOA) is one of the most prevalent and disabling diseases worldwide, affecting more than 32 million Americans today and projected to impact 78 million Americans by 2040. There are currently no approved disease modifying therapies; treatment is largely limited to pain relief, intra-articular steroids, or surgery, and the burden increases sharply with age. By age 60, KOA affects roughly 30% of the population, and about half of knee OA patients are 60 years and older. This demographic is expanding with global aging trends, underscoring the need for new, durable therapies. Announcement • Apr 22
Enlivex Ltd Announces Regulatory Approval for Phase 2B Trial of Allocetra in Age-Related Primary Moderate-To-Severe Knee Osteoarthritis Enlivex Ltd. had received Clinical Trial Application (CTA) approval by the Danish Medicines Agency (DKMA) for the Phase 2b trial of Allocetra, the Company's clinical-stage immunotherapy, for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis. The planned global, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial, recently approved by the FDA, has been designed to evaluate the efficacy and safety of intra-articular injections of Allocetra in patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis, which is one of the most prevalent and disabling diseases worldwide, affecting more than 32 million Americans today and projected to impact 78 million Americans by 2040. The clinical trial is designed to enroll patients from clinical centers in the United States, Denmark and Poland. The Phase 2b trial has been designed to be statistically powered to evaluate key efficacy endpoints, including change from baseline in pain and physical function compared with placebo, measured at three- and six-months periods following treatment. Additional endpoints include changes in quality-of-life measures and functional mobility assessments. New Risk • Mar 26
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 74% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 74% per year for the foreseeable future. High level of non-cash earnings (129% accrual ratio). Shareholders have been substantially diluted in the past year (over 9x increase in shares outstanding). Revenue is less than US$1m. 
